Emerging and investigational drugs for premature ejaculation

Area of Science:

• Pharmacology
• Urology
• Neuroscience

Background:

• Premature ejaculation (PE) treatment has evolved from psychotherapy to pharmacotherapy.
• Current drug treatments target neurotransmitters like serotonin, dopamine, and oxytocin.

Purpose of the Study:

• To review emerging interventions and contemporary data for PE treatment.
• To evaluate the efficacy and safety of various pharmacotherapeutic agents.

Main Methods:

• Evidence-based medicine principles were applied to review clinical studies.
• Critically appraised data from well-controlled studies on PE treatments.

Main Results:

• Selective serotonin reuptake inhibitors (SSRIs) are effective and safe first-line treatments for PE, with daily dosing yielding better results than on-demand use.
• Integrated pharmacotherapy and cognitive behavioral therapy (CBT) may enhance outcomes.
• PDE-5 inhibitors are suitable for acquired PE with erectile dysfunction (ED).
• Dapoxetine, off-label SSRIs, tramadol, and topical anesthetics are currently supported by evidence.

Conclusions:

• SSRIs are established as a primary medical treatment for PE.
• Future research may yield novel on-demand medications targeting multiple receptors.
• Further research is needed for treatments like α1-adrenoceptor antagonists.